Christoph Naber
Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jeger R, Weilenmann D, Rickli H, Hansen K, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Vuilliomenet A, Pedrazzini G, Pfisterer M, Vogt D, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz D, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PloS one 2019; 14:e0210821.
Jan 15, 2019Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II
Jan 15, 2019PloS one 2019; 14:e0210821
Jeger Raban V, Weilenmann Daniel, Rickli Hans, Hansen Kim Wadt, Rickenbacher Peter, Conen David, Müller Christian, Osswald Stefan, Gilgen Nicole, Vuilliomenet André, Pedrazzini Giovanni, Pfisterer Matthias, Vogt Deborah R, Galatius Søren, Abildgaard Ulrik, Naber Christoph, Alber Hannes, Eberli Franz, Kurz David J, Kaiser Christoph
Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Kaiser C, Vuillomenet A, Steiner M, von Felten S, Vogt D, Wadt Hansen K, Rickenbacher P, Conen D, Müller C, Buser P, Hoffmann A, Pfisterer M, Weilenmann D, Rickli H, Galatius S, Jeger R, Gilgen N, Skov Jensen J, Naber C, Alber H, Wanitschek M, Eberli F, Kurz D, Pedrazzini G, Moccetti T, BASKET-PROVE II study group. Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial. Circulation 2014; 131:74-81.
Nov 19, 2014Long-term efficacy and safety of biodegradable-polymer biolimus-eluting stents: main results of the Basel Stent Kosten-Effektivitäts Trial-PROspective Validation Examination II (BASKET-PROVE II), a randomized, controlled noninferiority 2-year outcome trial
Nov 19, 2014Circulation 2014; 131:74-81
Kaiser Christoph, Vuillomenet André, Steiner Martin, von Felten Stefanie, Vogt Deborah R, Wadt Hansen Kim, Rickenbacher Peter, Conen David, Müller Christian, Buser Peter, Hoffmann Andreas, Pfisterer Matthias, Weilenmann Daniel, Rickli Hans, Galatius Soeren, Jeger Raban, Gilgen Nicole, Skov Jensen Jan, Naber Christoph, Alber Hannes, Wanitschek Maria, Eberli Franz, Kurz David J, Pedrazzini Giovanni, Moccetti Tiziano, BASKET-PROVE II study group
Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
Jeger R, Gilgen N, Vuilliomenet A, Jensen J, Rickli H, Pedrazzini G, Naber C, Galatius S, Eberli F, Alber H, Pfisterer M, Kaiser C. Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design. Am Heart J 2012; 163:136-41.e1.
Feb 1, 2012Newest-generation drug-eluting and bare-metal stents combined with prasugrel-based antiplatelet therapy in large coronary arteries: the BAsel Stent Kosten Effektivitäts Trial PROspective Validation Examination part II (BASKET-PROVE II) trial design
Feb 1, 2012Am Heart J 2012; 163:136-41.e1
Jeger Raban, Gilgen Nicole, Vuilliomenet André, Jensen Jan Skov, Rickli Hans, Pedrazzini Giovanni, Naber Christoph, Galatius Søren, Eberli Franz, Alber Hannes, Pfisterer Matthias, Kaiser Christoph